Aardvark Therapeutics, Inc., Completes $29m Series B Funding Led By Sorrento Therapeutics And Including Existing Investors And The Foundation For Prader-Willi Research
Funds will support three Phase 2 clinical trials of Aardvark's lead compound to be initiated this year and advance additional products in the pipeline
SAN DIEGO, Aug. 5, 2021 -- (Healthcare Sales & Marketing Network) -- Aardvark Therapeutics, Inc., a c... Biopharmaceuticals, Venture Capital Aardvark Therapeutics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Funding | Marketing | Pharmaceuticals | Prader-Willi Syndrome | Venture Capital